

# Eric M Mucker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624811/publications.pdf>

Version: 2024-02-01

33  
papers

1,926  
citations

331538

21  
h-index

377752

34  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1990  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. <i>Nature</i> , 2004, 428, 182-185.	13.7	405
2	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. <i>JCI Insight</i> , 2020, 5, .	2.3	186
3	Nonhuman Primates Are Protected from Smallpox Virus or Monkeypox Virus Challenges by the Antiviral Drug ST-246. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2620-2625.	1.4	139
4	Monkeypox virus detection in rodents using real-time 3'â€²-minor groove binder TaqManÂ® assays on the Roche LightCycler. <i>Laboratory Investigation</i> , 2004, 84, 1200-1208.	1.7	124
5	Smallpox and pan -Orthopox Virus Detection by Real-Time 3'â€²-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms. <i>Journal of Clinical Microbiology</i> , 2004, 42, 601-609.	1.8	122
6	ST-246 Antiviral Efficacy in a Nonhuman Primate Monkeypox Model: Determination of the Minimal Effective Dose and Human Dose Justification. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1817-1822.	1.4	112
7	Smallpox Vaccine Does Not Protect Macaques with AIDS from a Lethal Monkeypox Virus Challenge. <i>Journal of Infectious Diseases</i> , 2005, 191, 372-381.	1.9	83
8	Efficacy of Tecovirimat (ST-246) in Nonhuman Primates Infected with Variola Virus (Smallpox). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6246-6253.	1.4	81
9	A Novel Respiratory Model of Infection with Monkeypox Virus in Cynomolgus Macaques. <i>Journal of Virology</i> , 2011, 85, 4898-4909.	1.5	61
10	Circulating microRNA profiles of Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 24496.	1.6	50
11	Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses. <i>BioMed Research International</i> , 2015, 2015, 1-31.	0.9	42
12	Inhibition of Monkeypox virus replication by RNA interference. <i>Virology Journal</i> , 2009, 6, 188.	1.4	41
13	Susceptibility of Marmosets ( <i>Callithrix jacchus</i> ) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease. <i>PLoS ONE</i> , 2015, 10, e0131742.	1.1	41
14	Intranasal monkeypox marmoset model: Prophylactic antibody treatment provides benefit against severe monkeypox virus disease. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006581.	1.3	39
15	Cytauxzoon felis infections are present in bobcats ( <i>Lynx rufus</i> ) in a region where cytauxzoonosis is not recognized in domestic cats. <i>Veterinary Parasitology</i> , 2008, 153, 126-130.	0.7	36
16	Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2171.	1.3	36
17	Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates. <i>PLoS ONE</i> , 2012, 7, e42353.	1.1	36
18	Virus-encoded miRNAs in Ebola virus disease. <i>Scientific Reports</i> , 2018, 8, 6480.	1.6	34

#	ARTICLE	IF	CITATIONS
19	Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomal Bovines. <i>Scientific Reports</i> , 2020, 10, 8764.	1.6	32
20	A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge. <i>Journal of Virology</i> , 2022, 96, JVI0150421.	1.5	31
21	Seroprevalence of Antibodies to <i>Toxoplasma gondii</i> in the Pennsylvania Bobcat ( <i>Lynx rufus rufus</i> ). <i>Journal of Wildlife Diseases</i> , 2006, 42, 188-191.	0.3	24
22	Euthanasia Assessment in Ebola Virus Infected Nonhuman Primates. <i>Viruses</i> , 2014, 6, 4666-4682.	1.5	22
23	In vivo imaging of cidofovir treatment of cowpox virus infection. <i>Virus Research</i> , 2007, 128, 88-98.	1.1	21
24	An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection. <i>Scientific Reports</i> , 2017, 7, 4679.	1.6	21
25	Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein. <i>Archives of Virology</i> , 2011, 156, 1877-1881.	0.9	17
26	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. <i>MBio</i> , 2022, 13, e0290621.	1.8	17
27	Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 847-858.	2.3	17
28	Particle-specific neutralizing activity of a monoclonal antibody targeting the poxvirus A33 protein reveals differences between cell associated and extracellular enveloped virions. <i>Virology</i> , 2020, 544, 42-54.	1.1	16
29	Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. <i>MAbs</i> , 2022, 14, 2002236.	2.6	14
30	Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood. <i>Virology Journal</i> , 2017, 14, 210.	1.4	10
31	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. <i>Journal of General Virology</i> , 2021, 102, .	1.3	6
32	Differentiation of Variola major and Variola minor variants by MGB-Eclipse probe melt curves and genotyping analysis. <i>Molecular and Cellular Probes</i> , 2009, 23, 166-170.	0.9	5
33	SARS-CoV-2 Doggybone DNA Vaccine Produces Cross-Variant Neutralizing Antibodies and Is Protective in a COVID-19 Animal Model. <i>Vaccines</i> , 2022, 10, 1104.	2.1	4